Autor: |
Sahoor Khan, Sourbha S. Dani, Joerg Hermann, Tomas.G. Neilan, Daniel J. Lenihan, Michael Fradley, Rohan Parikh, Saafi Khan, Anita Deswal, Jennifer Liu, Ana Barac, Sherif Labib, Arjun Majithia, Anju Nohria, Suzanne J. Baron, Sarju Ganatra |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
International Journal of Cardiology: Heart & Vasculature, Vol 44, Iss , Pp 101165- (2023) |
Druh dokumentu: |
article |
ISSN: |
2352-9067 |
DOI: |
10.1016/j.ijcha.2022.101165 |
Popis: |
Background: Surgical therapy has been a long-standing option for valvular heart disease, in patients with history of cancer, it carries an increased risk of complications. Objectives: Transcatheter edge-to-edge repair (TEER) for mitral regurgitation, represents a less invasive option. However, patients with history of cancer have generally been excluded from trials. Methods: A retrospective cohort analysis was performed on de-identified, aggregate patient data from the TriNetX research network. Patients 18 ≥ years of age, who had undergone TEER between January 1, 2013 and May 19, 2021, were identified using the CPT codes and divided into two cohorts based on a history of cancer. Subgroup analysis was performed based on history of systemic antineoplastic therapy. Odds ratio and log-rank test were used to compare the outcomes over 1 and 12-months. Results: In matched cohorts (503 patients in each, mean age 77.7 years, men 55 vs 58 %, white 84 vs 87 % in non-cancer and cancer cohorts respectively), the risk of heart failure exacerbation, all-cause mortality and all-cause hospitalizations were similar at 1 and 12 months among patients undergoing TEER. Risk of major complications (ischemic stroke, blood product transfusion and cardiac tamponade) were also similar. In the cancer cohort, hematologic/lymphoid malignancies were the most common (28.0 %) and 12.5 % patients had a history of metastatic cancer. There was no significant difference in heart failure exacerbation or all-cause mortality based on history of systemic antineoplastic therapy. Conclusions: Overall outcomes following TEER are similar in patients with a history of cancer and should be considered in selected patients in this population. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|